Iovance Biotherapeutics, Inc. announces the FDA acceptance of its BLA submission
In another step toward commercial approval, Iovance Biotherapeutics, Inc. announced yesterday that with the FDA acceptance of its BLA submission for its lifileucel cell therapy and its Priority Review status, its PDUFA date is November 25 of this year. Furthermore, the FDA is not currently planning to hold an advisory committee meeting to discuss this application and, after a preliminary review, has not at this time identified any potential review issues. So close now!
